Investors who have suffered losses can register their claims through the designated platform. On April 27, 2026, Dalian Bio-Chem Company Limited (hereinafter referred to as "the Company") received a "Notice of Case Filing" (No.: Zheng Jian Li An Zi 0212026001) from the China Securities Regulatory Commission (CSRC). The CSRC has decided to initiate an investigation into the Company due to suspected violations of information disclosure laws and regulations, in accordance with the Securities Law of the People's Republic of China and the Administrative Penalty Law of the People's Republic of China. This situation may create an opportunity for certain investors to file compensation claims.
Legal professionals suggest that, based on the new judicial interpretations concerning securities misrepresentation, the previous pre-condition procedures have been explicitly abolished. Investors who have incurred losses due to misrepresentation by a listed company can file civil compensation lawsuits with the competent court to protect their legitimate rights and interests. The scope of compensable losses may include investment value differential losses, stamp duty, and commission fees.
Provisional claim conditions are as follows: investors who purchased shares on or before April 27, 2026, and subsequently sold them after April 27, 2026, or continue to hold them at a loss (the final outcome of the claim is subject to the court's ruling).
Investors should prepare the following materials: a copy of their ID card, a confirmation form of securities account opening information (original copy stamped by the securities company's business department), and a detailed record of securities transactions (from the first purchase of the stock to the present, stamped by the securities company's business department; if shares are still held, the current holding quantity must also be printed).
Comments